Latest Close
$25.69
Stock Hub
LBRX
LB Pharmaceuticals Inc
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. Use the sections below to move between chart, technical analysis, fundamentals, and news.
1y Change
$8.39 (+48.50%)
Market Cap
$736,656,320.00
Sector
Healthcare
Industry
Biotechnology
Recommendation
strong_buy
52W Range
$13.36 to $27.55
Target Mean Price
$45.75
Beta
Not available
Trailing P/E
Not available
Forward P/E
-6.48
Price / Book
2.16
Company Overview
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.